Paper Details

  1. Home
  2. Paper Details

Ivosidenib Deemed Safe, Effective in AML.

Author:

NewsMedia reports that provide information on the latest events and information. Newspapers, television, and the Internet are the main media.
CommentA short article/note that provides an opinion/perspective/interpretation on a published paper/topic.

Overview

Ivosidenib is a drug that shows promise in inducing remission in patients with relapsed or refractory acute myeloid leukemia characterized by *IDH1* mutations. In a phase I study, 30.4% of patients achieved complete remission or complete remission with partial hematologic recovery. The most common side effects were prolonged QT interval and IDH differentiation syndrome.
Paper Details　
Original Abstract of the Article :
A phase I study suggests that ivosidenib can induce remission in patients with relapsed or refractory acute myeloid leukemia characterized by <i>IDH1</i> mutations. The drug spurred complete remission or complete remission with partial hematologic recovery in 30.4% of patients. The most common side ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1158/2159-8290.CD-NB2018-082

データ提供：米国国立医学図書館（NLM）

Ivosidenib: A Promising Treatment for AML

This study explores the potential of a new drug, ivosidenib, as a treatment for acute myeloid leukemia (AML), a serious and often aggressive type of cancer. The study investigates the efficacy and safety of ivosidenib in patients with relapsed or refractory AML characterized by IDH1 mutations.

Ivosidenib’s Impact: Inducing Remission in AML

The researchers find that ivosidenib demonstrates promising efficacy in inducing remission in patients with IDH1-mutated AML. The study highlights the significant proportion of patients who achieved complete remission or complete remission with partial hematologic recovery. This finding provides hope for patients with this challenging type of leukemia, suggesting that ivosidenib may offer a valuable treatment option.

Navigating the Landscape of Cancer Therapies

This study exemplifies the dynamic nature of cancer research, showcasing the continuous development of new drugs and therapies. It underscores the importance of personalized medicine, tailoring treatment approaches to the specific genetic characteristics of each patient. The study encourages continued research to further optimize the use of ivosidenib and other targeted therapies for AML.

Dr.Camel's Conclusion

Just as a camel can adapt to the harsh desert conditions, researchers are tirelessly seeking new therapies to combat the formidable challenges of cancer. This study offers a beacon of hope for patients with AML, highlighting the potential of ivosidenib to offer a promising treatment option for this complex and often aggressive disease.

Date :
  1. Date Completed 2019-07-18
  2. Date Revised 2019-07-18
Further Info :

Pubmed ID

29934313

DOI: Digital Object Identifier

10.1158/2159-8290.CD-NB2018-082

Related Literature

Article Analysis
・Side Effects of ivosidenib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.